Published in Am J Transl Res on February 12, 2010
Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert Opin Investig Drugs (2012) 1.10
Acetylation of retinal histones in diabetes increases inflammatory proteins: effects of minocycline and manipulation of histone acetyltransferase (HAT) and histone deacetylase (HDAC). J Biol Chem (2012) 0.97
Minocycline prevents impaired glial glutamate uptake in the spinal sensory synapses of neuropathic rats. Neuroscience (2010) 0.95
Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol (2012) 0.90
Interleukin-4 and melatonin ameliorate high glucose and interleukin-1β stimulated inflammatory reaction in human retinal endothelial cells and retinal pigment epithelial cells. Mol Vis (2014) 0.84
Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. J Ocul Biol Dis Infor (2012) 0.79
Matrix metalloproteinases in the mouse retina: a comparative study of expression patterns and MMP antibodies. BMC Ophthalmol (2015) 0.76
Diabetes enhances the efficacy of AAV2 vectors in the retina: therapeutic effect of AAV2 encoding vasoinhibin and soluble VEGF receptor 1. Lab Invest (2015) 0.75
Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A. Am J Transl Res (2016) 0.75
Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29
The matrix-degrading metalloproteinases. Bioessays (1992) 4.84
Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol (1961) 3.80
Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes (2006) 3.31
Molecular architecture of basement membranes. FASEB J (1990) 3.28
Diabetic retinopathy: more than meets the eye. Surv Ophthalmol (2002) 2.95
Matrix metalloproteinases: structures, evolution, and diversification. FASEB J (1998) 2.74
Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med (1987) 2.50
Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications. Proc Natl Acad Sci U S A (1989) 2.45
Abnormal angiogenesis in diabetes mellitus. Med Res Rev (2003) 2.41
Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res (2003) 2.37
Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci (2001) 2.24
Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology (2008) 2.11
New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem (2000) 2.07
Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest (2005) 1.92
Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res (2001) 1.87
Oxidative stress and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Rev Endocr Metab Disord (2008) 1.66
Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des (2007) 1.45
Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population--the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. Diabet Med (2008) 1.40
Electrophysiological changes in juvenile diabetics without retinopathy. Arch Ophthalmol (1990) 1.34
Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci (2008) 1.32
The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs (2004) 1.26
Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci (1999) 1.24
The development of retinopathy in sucrose-fed and streptozotocin-diabetic rats. Diabetologia (1976) 1.22
Mediators of ocular angiogenesis. J Genet (2009) 1.17
Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (2003) 1.09
Matrix metalloproteinases and diabetic vascular complications. Angiology (2005) 1.01
Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol (1999) 1.01
Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2008) 0.98
Care of vision and ocular health in diabetic members of a national diabetes organization: a cross-sectional study. BMC Health Serv Res (2008) 0.97
Detection of early retinal changes in diabetes by vitreous fluorophotometry. Diabetes (1979) 0.97
Disruption of blood-retinal barrier in experimental diabetic rats: an electron microscopic study. Exp Eye Res (1980) 0.94
Electrophysiologic assessment of photoreceptor function in patients with primary open-angle glaucoma. J Glaucoma (2000) 0.94
Electroretinographic oscillatory potentials in insulin-dependent diabetes patients: A long-term follow-up. Acta Ophthalmol Scand (2002) 0.86
High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin (2003) 0.86
Oscillatory potentials and the b-Wave: partial masking and interdependence in dark adaptation and diabetes in the rat. Graefes Arch Clin Exp Ophthalmol (2007) 0.85
Fibronectin-induced COX-2 mediates MMP-2 expression and invasiveness of rhabdomyosarcoma. Biochem Biophys Res Commun (2004) 0.82
Minocycline with aspirin: an approach to attenuate diabetic nephropathy in rats. Ren Fail (2011) 0.79
In vitro evaluation of hepatic and extra-hepatic metabolism of coumarins using rat subcellular fractions: correlation of in vitro clearance with in vivo data. Drug Metabol Drug Interact (2008) 0.77
Potentiation of aspirin-induced cerebroprotection by minocycline: a therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia. Diab Vasc Dis Res (2011) 0.76
The potentials of selected therapeutic targets for inflammation: a snapshot. Recent Pat Inflamm Allergy Drug Discov (2012) 0.75
Amelioration of diabetic nephropathy by orange peel extract in rats. Nat Prod Res (2014) 0.75